Last reviewed · How we verify
insulin degludec + liraglutide
This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism.
This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | insulin degludec + liraglutide |
|---|---|
| Also known as | ideglira |
| Sponsor | Hospital Universitario San Ignacio |
| Drug class | Basal insulin + GLP-1 receptor agonist combination |
| Target | Insulin receptor (degludec); GLP-1 receptor (liraglutide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin degludec is a long-acting basal insulin that provides steady background glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial hyperglycemia while supporting weight loss.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Hypoglycemia
- Vomiting
- Diarrhea
- Headache
- Injection site reactions
Key clinical trials
- Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus (PHASE4)
- A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes (PHASE3)
- A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects (PHASE1)
- The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- insulin degludec + liraglutide CI brief — competitive landscape report
- insulin degludec + liraglutide updates RSS · CI watch RSS
- Hospital Universitario San Ignacio portfolio CI